Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The Emergo Group is now in the mix. They are ready to start and proceed with their international plans for the SNDY international expansion. Get ready to see positive SNDY News in the new year!
As part of the process to obtain the CE Mark, Solos Endoscopy retained Emergo Group to act as the Company's authorized representative in Europe. Emergo Group will provide Solos assistance related to communications with authorities and importation of Solos instruments into Europe.
SNDY Alert - Don't forget the Emergo Group. They will begin their aggressive SNDY international expansion plan in 2015. Partnership waiting for global sales.
New Year/Canada/Europe/Partnership - News Soon!
SNDY NEWS SOON!
Stay Tuned! Major events happening behind the scenes and SNDY is getting set to break the news blackout.
SNDY News SOON! Much sooner than sooner than soon.
Actually, it will be SOONER Than SOON! Stay tuned for SOON.
I didn't call for News last week or this week. I said News Soon!
Be Alert for News -SNDY moving up.
Big News coming SOON!
SNDY ALERT! - News Coming SOON! There will be knashing of teeth and heads exploding with frustrated rage from those who are so desperately hoping for SNDY to fail!
Some of both.
It means soon, very soon!
Major News coming not just SOON, but very SOON!
That news as well as partnership news coming soon. Europe in play as well.
Solos Endoscopy's MamoView(R) to Participate at the Dr. Susan Love Research Foundation Symposium on the Breast
Accesswire
BOSTON, MA / ACCESSWIRE / November 24, 2014 / Solos Endoscopy, Inc. (OTC Pink: SNDY) (SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, is pleased to announce that it has been invited to participate at the 8th International Dr. Susan Love Research Foundation Symposium on the Breast.
Prominent Doctors from around the Country will be discussing the keys to identifying the cause of breast cancer and determining methods of prevention. Researchers believe that Breast Cancer Prevention lies in understanding the normal human breast and how it develops malignancy. New technologies for DNA/RNA analysis and procedures to sample the human breast are opening up promising new avenues for exploration. The Solos Endoscopy MammoView(R) Breast Endoscopy System can offer women a positive prognosis for recovery by detecting breast cancer up to six times faster than conventional methods. The MammoView(R) Breast Endoscopy System allows physicians to distinguish and inspect suspicious pre-cancerous lesions undetectable by other methods.
The International Symposium on the Breast calls upon a multidisciplinary and international group of iconoclastic researchers, clinical scientists, and advocates, and challenges participants to formulate new technical approaches to the study of the normal and high-risk breast. Some of the confirmed Speakers at the symposium will include the following:
Mina Bissell, PhD; Lawrence Berkeley National Laboratory
Ellen Carpenter, PhD; University of California Los Angeles
Robert Chatterton, PhD; Northwestern University
Susan Clare, MD, PhD; Northwestern University
William B. Coleman, PhD; University of North Carolina
Sheldon Feldman, MD; Columbia University
Barry Gusterason, PhD; Western Infirmary, Glasgow, Scotland
Sarah Highlander, PhD; Baylor College of Medicine
Ann Hopkins, PhD; Royal College of Surgeons, Ireland
Donald Ingbert, MD, PhD; Harvard University
"I would like to thank the Dr. Susan Love Research Foundation for inviting us to participate in this extremely important Symposium on Breast Health. We believe the early detection that the MamoView(R) affords its patients gives women the most options when it comes to determining their final treatment," stated Robert Segersten, President of Solos Endoscopy.
The Certification Body of TUV America has certified that Solos Endoscopy has established and is maintaining a quality management system that meets the requirements of the European Union and Canada. The initial Certification came at the conclusion of a lengthy audit with TUV SUD America this past year. The annual audit included a comprehensive review of the Solos Endoscopy's Quality Manual and 28 Quality System Procedures for compliance with the international quality system standard ISO 13485:2003, to the European Union's Medical Device Directive (MDD 93/42/EEC) and to the Canadian Medical Device Regulations (SOR/98-282).
Solos Endoscopy has posted its Certificate from TUV America on its website (http://www.solosendoscopy.com)
About Solos Endoscopy, Inc.:
Solos Endoscopy has celebrated its 25th year of providing quality innovative healthcare instruments to hospitals across the country. For more than 25 years, from medical schools to hospitals, surgeons have trusted Solos Endoscopy to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.
CONTACT:
Solos Endoscopy, Inc.
Investor Relations
(617) 360-9719
SOURCE: Solos Endoscopy, Inc.
Major News coming SOON! Canada/Europe/Strategic Partnership - Watch what happens once the 40 to 50 million plus shares the resident one tick flipper's have been obviously manipulating the price with are burned through at .0005 to .0007, there will be big hops in price back up over .003.
I find it much more gratifying to have peeps here mad at me for posting good things about the company than I did when peeps here were mad at me for posting bad things about the company! Lolol... Gotta love the stinky pink sheets!
They are selling them now. Check it out -
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=108089884
None of those. It will happen SOON.
Good for you! Just remember, that no matter how good any news is, it won't be good enough for some. Even if SNDY discovered a cure for cancer, some would loudly complain, and ask why didn't they discover a cure for heart disease and cancer.
Try looking at your actual calendar. That report is for the Quarter ending September 30th. The increases in sales after the delays from the component manufacturer problem was solved, as well as new Mammoview orders, started occurring in October and November. A quarterly report that ends in September, doesn't reflect sales from two months after that quarter ended, it reflects sales from before September 30th.
Dude, I'm looking at this, among other things -
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=108089884
The recent sales increases that are positively impacting current sales figures after the company resolved the parts inventory problems that negatively impacted sales earlier this year, as well as the $300.000 thus far in new Mammoview orders, started impacting the bottom line in October and continue in November, which won't be reflected in filings until next quarterly report comes out.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=108089884
Thanks for that observation. Yes, SNDY's sales are increasing domestically and they are not expanding into Canada and Europe!
Thanks! Yes, it proves sales are continuing now, and thousands of more dollars in sales are being added with more coming from Canada and Europe!
Thanks for posting that! That is a fantastic comparison. That old news confirms past purchase orders for the Mammoview, and proves that the sales and purchase orders from NEW hospitals are increasing by hundreds of thousands of dollars as stated in the recent PR!
http://www.eteligis.com/ViewSubmission.aspx?submissionRequest=28459
.
Things have finally changed for the positive -Sales are increasing and will continue to increase both domestic and foreign.
Solos Endoscopy’s MamoView(R) Demonstrates Strong Growth Potential
Nov 12, 2014 7:14:14 AM PST
BOSTON, MA, United States, 11/12/2014 - - BOSTON, MA Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY),a provider of quality innovative healthcare instruments to Hospitals across the Country, is pleased to announce that the company's MamoView® Breast Endoscopy System has shown strong growth over the past 18 months. Solos management has reported that MamoView(R) product sales has increased as a percentage of gross sales and in the past 18 months the company has received more than $300,000 in MamoView(R) orders from hospitals nationwide.
The Solos Endoscopy MammoView(R) Breast Endoscopy System can help give women the best prognosis for recovery by detecting breast cancer up to six times faster than conventional methods. The MammoView(R) Breast Endoscopy System allows physicians to distinguish and inspect suspicious pre-cancerous lesions undetectable by other methods.
"Management expects sales of the MamoView(R) to increase in the future as more physicians are trained in the procedure," stated Robert Segersten, President of Solos Endoscopy.
There are several teaching and research hospitals that are currently utilizing the MamoView(R) Breast Endoscopy System across the country. Management will be working with these teaching hospitals to collect data and identify new surgeons in an effort to increase sales.
Solos Endoscopy instruments are FDA approved. Solos Endoscopy intends to place the CE Mark on its entire MammoView(R) instrument line following its successful Audit with TUV America. Solos Endoscopy has posted its Certificate from TUV America on its website (http://www.solosendoscopy.com)
About Solos Endoscopy, Inc.:
Solos Endoscopy has celebrated its 25th year of providing quality innovative healthcare instruments to hospitals across the country. For more than 25 years, from medical schools to hospitals, surgeons have trusted Solos Endoscopy to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.
Forward-Looking Statements:
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.
CONTACT:
Solos Endoscopy, Inc.
Investor Relations
(617) 360-9719
SOURCE: Solos Endoscopy, Inc.
http://www.eteligis.com/ViewSubmission.aspx?submissionRequest=28459
.
SNDY - Negotiating sales contracts in Canada. Europe next.
You're right, I see the date now in the filing. So the filing was due on the 16th, not the 14th, and they have 5 days from that date which is the 21st. The date they posted the notice of late filing is the 14th. They have until the 21st, however they could complete it earlier than the 21st, but that is probably unlikely.
FIling due tomorrow. Be alert for News to follow filing.
Thanks for posting that! That is a fantastic comparison. That old news confirms past purchase orders for the Mammoview, and proves that the sales and purchase orders from NEW hospitals are increasing by hundreds of thousands of dollars as stated in the recent PR
http://www.eteligis.com/ViewSubmission.aspx?submissionRequest=28459
.
Solos Endoscopy’s MamoView(R) Demonstrates Strong Growth Potential
Nov 12, 2014 7:14:14 AM PST
BOSTON, MA, United States, 11/12/2014 - - BOSTON, MA Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY),a provider of quality innovative healthcare instruments to Hospitals across the Country, is pleased to announce that the company's MamoView® Breast Endoscopy System has shown strong growth over the past 18 months. Solos management has reported that MamoView(R) product sales has increased as a percentage of gross sales and in the past 18 months the company has received more than $300,000 in MamoView(R) orders from hospitals nationwide.
The Solos Endoscopy MammoView(R) Breast Endoscopy System can help give women the best prognosis for recovery by detecting breast cancer up to six times faster than conventional methods. The MammoView(R) Breast Endoscopy System allows physicians to distinguish and inspect suspicious pre-cancerous lesions undetectable by other methods.
"Management expects sales of the MamoView(R) to increase in the future as more physicians are trained in the procedure," stated Robert Segersten, President of Solos Endoscopy.
There are several teaching and research hospitals that are currently utilizing the MamoView(R) Breast Endoscopy System across the country. Management will be working with these teaching hospitals to collect data and identify new surgeons in an effort to increase sales.
Solos Endoscopy instruments are FDA approved. Solos Endoscopy intends to place the CE Mark on its entire MammoView(R) instrument line following its successful Audit with TUV America. Solos Endoscopy has posted its Certificate from TUV America on its website (http://www.solosendoscopy.com)
About Solos Endoscopy, Inc.:
Solos Endoscopy has celebrated its 25th year of providing quality innovative healthcare instruments to hospitals across the country. For more than 25 years, from medical schools to hospitals, surgeons have trusted Solos Endoscopy to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.
Forward-Looking Statements:
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.
CONTACT:
Solos Endoscopy, Inc.
Investor Relations
(617) 360-9719
SOURCE: Solos Endoscopy, Inc.
http://www.eteligis.com/ViewSubmission.aspx?submissionRequest=28459
It will. The company has worked too long and hard for the CE Certification to squander it after they achieved the benchmark. The company is slow moving, but they have thus far step by step achieved their stated goals including increasing domestic sales and obtaining the much coveted CE Certifications necessary to expand sale of their FDA approved products to Canada and Europe.
IMO - Financial report being delayed will now have the timing of their release to coincide with other pending News regarding Canadian expansion and sales increases.
Boston shareholders correctly predicted the increase in USA sales and now predict the quarterly filing due out in the next few days with positive sales data will be followed by more Canadian expansion news. Negotiations with expansion partnership entity and Europe still in play. Don't forget the Emergo Group. News SOON.
Absolutely. The Mammoview sales are increasing here in the USA and with the CE Mark attached, will be starting in Canada and Europe as well.